eligibility_summary
Eligible: adults 18–65 with histologically/cytologically confirmed advanced NPC (AJCC 8th III–IVA, excluding T3–4N0/T3N1), ECOG 0–1, adequate organ/bone marrow function, consent. Exclude: other malignancy <5y (except cured skin/in situ), CHF/LVEF<50%, active HBV/HCV unless controlled, serious lung disease or active/recent (≤1y) TB, HIV or syphilis, severe/active infection, systemic autoimmune disease in 2y, pregnant/lactating, prior NPC RT/chemo/surgery, drug allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III, multicenter, open-label RCT in high‑risk locally advanced nasopharyngeal carcinoma comparing two induction regimens, each combined with immunotherapy and anti‑EGFR therapy, then radiotherapy. Arms: TPC (nab‑paclitaxel taxane + cisplatin platinum + capecitabine fluoropyrimidine prodrug of 5‑FU) vs GP (gemcitabine nucleoside analog antimetabolite + cisplatin), both with nimotuzumab (anti‑EGFR IgG1 monoclonal antibody) and a PD‑1 inhibitor (toripalimab, protocol text also lists nivolumab). Mechanisms/targets: nimotuzumab blocks EGFR signaling (RAS/MAPK, PI3K/AKT) and can mediate ADCC in EGFR‑expressing tumor cells, toripalimab/nivolumab block PD‑1 to reactivate exhausted T cells. Chemotherapy targets: DNA crosslinking (cisplatin), microtubules (nab‑paclitaxel), thymidylate synthase via 5‑FU (capecitabine), and DNA synthesis/RNR (gemcitabine). Targeted cells/pathways: EGFR+ tumor cells, PD‑1+ T cells, and proliferating tumor cell division/DNA replication.